^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Cu-67 SAR-Bombesin

    i
    Other names: Cu-67 SAR-Bombesin, 67Cu-SAR-BBN, [67Cu]Cu(SAR-BBN)
    Associations

    News

    Trials
    Company:
    Clarity Pharma
    Drug class:
    GRPR antagonist
    Related drugs:
    Associations

    News

    Trials
    1year
    COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer. (ASCO-GU 2024)
    Prostate-specific membrane antigen (PSMA)-targeted theranostic agents, 68Ga-PSMA-11 and 177Lu-PSMA-617, have been approved by the FDA for patient selection and therapy for patients with mCRPC, respectively. At the time of submission of this abstract, cohort 1 is open for enrollment. Clinical trial information: NCT05633160.
    Metastases
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Cu-67 SAR-Bombesin
    over1year
    64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) (clinicaltrials.gov)
    P1/2, N=38, Recruiting, Clarity Pharmaceuticals Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Cu-67 SAR-Bombesin